Clinical Trial Detail

NCT ID NCT02715531
Title A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

gastroesophageal junction adenocarcinoma

pancreatic cancer

esophageal cancer

hepatocellular carcinoma

gastric adenocarcinoma

Therapies

Capecitabine

Atezolizumab + Cisplatin + Fluorouracil

Atezolizumab + Gemcitabine + Nab-paclitaxel

Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin

Atezolizumab + Bevacizumab

Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: senior adult

Additional content available in CKB BOOST